Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Peter Voorhees, MD, is Director of Outreach and Clinical Operations for Hematologic Malignancies and a Member of the Plasma Cells Disorder Program at the Levine Cancer Institute in Charlotte, North Carolina. Dr. Voorhees is an internationally recognized thought leader in multiple myeloma whose research focuses on the clinical development of novel therapeutic strategies for the treatment of newly diagnosed and relapsed/refractory multiple myeloma. He is board certified in Hematology and a member of the American Society of Hematology, American Society of Clinical Oncology and International Myeloma Working Group. He is also a member of the Multiple Myeloma Committee of the Alliance Cooperative Group. He has published numerous original articles, reviews and book chapters in multiple myeloma. He received his medical degree from the University of Michigan, continued his postgraduate studies with an internal medicine residency/chief residency at the University of Wisconsin, and completed a hematology-oncology fellowship at the University of North Carolina at Chapel Hill. Prior to joining the Levine Cancer Institute, he was an Associate Professor in the Department of Internal Medicine, Division of Hematology-Oncology, at the University of North Carolina at Chapel Hill where he led their Multiple Myeloma Program.

Dr. Hartley-Brown is an emerging leader in the field of Multiple Myeloma. She is an Associate Physician at Harvard Medical School and Assistant Professor & Medical Oncologist who specializes in treating patients with multiple myeloma. She practices clinical care at the Jerome Lipper Multiple Myeloma Center at Dana-Farber Cancer Institute. Multiple myeloma is an incurable cancer that affects Black Americans approximately twice more than Caucasians. Dr. Hartley-Brown has written several publications and has been a clinical research investigator for numerous clinical studies that has contributed to the advancement of clinical care for patients with multiple myeloma and plasma cell dyscrasias. As a Black female physician, she is dedicated to ensuring that the care for the myeloma community is equitable and affords all patients with myeloma an optimal level of care regardless of background, race or socioeconomic status.

“As both a clinician and a researcher, my job gives me a great sense of purpose. I feel honored to help others combat their illnesses, whether directly with patients and their families or by contributing to the clinical research that will improve our understanding of disease and develop novel therapies to improve outcomes.” Dr. Ferreri is board certified in internal medicine. He focuses on hematology and medical oncology (blood disorders and cancer). Conditions he treats include plasma cell disorders, monoclonal gammopathy of undetermined significance (a disorder known as MGUS), light chain amyloidosis (a plasma cell disorder that can have multi-organ system involvement), Waldenstrom macroglobulinemia (a blood cell cancer) and multiple myeloma. He was initially drawn to hematology-oncology during his undergraduate studies. Through personal experiences, he became passionate about the humanistic aspects of cancer medicine. He strives to help patients understand their illnesses and treatments with clear and honest communication. Dr. Ferreri is a clinical assistant professor in the Department of Hematologic Oncology and Blood Disorders at Atrium Health Levine Cancer. His research focuses on clinical and translational research involving multiple myeloma and CAR T-cell therapy. He has authored multiple publications and presented at conferences relating to CAR T-cell therapy for multiple myeloma. Dr. Ferreri has received an American Society of Hematology (ASH) Abstract Achievement Award and an International Myeloma Society (IMS) Young Investigator Award. He received his bachelor’s degree in molecular genetics and his medical degree at The Ohio State University. He completed residency at Duke University and a fellowship at The University of Texas MD Anderson Cancer Center, where he was named LBJ Oncology Clinical Fellow of the Year. Outside of work, he is an avid sports fan who enjoys restaurants and the Blue Ridge Mountains. He loves spending time with his wife, family, friends and dog, a Cavapoo named Benny.

“I truly feel honored to care for my patients. I know firsthand how overwhelming a cancer diagnosis can be. I strive to make sure my patients understand their disease and how we’re going to treat it. I want them to feel informed and rest assured they are getting the best care.” Dr. Paul is board certified in internal medicine and hematology (blood disorders). Dr. Paul is an assistant professor in the Division of Plasma Cell Disorders at the Department of Hematologic Oncology and Blood Disorders at Atrium Health. His research interests include translational research and clinical trial options for new plasma cell disorder treatments. He became fascinated with plasma cell disorders while conducting lab based research on mechanisms of acquired resistance to myeloma therapies. This inspired him to choose a practice area that would allow him to use his laboratory experiences in direct patient care affecting diverse populations. Dr. Paul received his medical degree at the University of Miami. He completed residency at the University of North Carolina and a fellowship at Duke University. In his free time, he enjoys spending time with his family, traveling, hiking, camping, woodworking and rooting for the Philadelphia Eagles.

Luciano J. Costa, M.D., Ph.D., serves as the Associate Director for Clinical Research at the O’Neal Comprehensive Cancer Center at UAB. Dr. Costa obtained his M.D. and subsequently Ph.D. from Universidade de Sao Paulo, Brazil. He then trained in hematology and medical oncology at the University of Colorado in Aurora and in blood and marrow transplantation at the Mayo Clinic in Rochester, Minnesota. Prior to joining UAB, Dr. Costa was an Associate Professor of Medicine at the Medical University of South Carolina where he co-chaired the Protocol Review Committee at Hollings Cancer Center. He was recruited to the O’Neal Comprehensive Cancer Center in 2014 as a Senior Clinical Investigator and currently directs the Multiple Myeloma and the Immune Effector Cellular Therapy programs. His primary research focus is the development of new therapies for plasma cell malignancies. Dr. Costa leads several multi-institutional and international projects exploring new cellular and immunotherapies and minimal residual disease in myeloma. He is regarded as an international leader in the field with more than 200 peer-reviewed abstracts and publications in high-impact journals such as Blood, Leukemia, the Journal of Clinical Oncology and The New England Journal of Medicine.